Skip to main content
In stock | Targeted Therapy

Milademetan

Oncology Type Both (Solid & Hematologic)
Drug Class / Mechanism MDM2 Inhibitor
No Image
Description

Milademetan is classified as a MDM2 Inhibitor, sourced for use within our Targeted Therapy portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Targeted Therapy
Oncology Type Both (Solid & Hematologic)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3